Helicobacter pylori and Dyspepsia

Nicholas J. Talley

University of Sydney, Penrith, New South Wales, Australia

It is clear that non-ulcer (or functional) dyspepsia is a heterogenous syndrome that includes a subset of patients with unrecognized gastroesophageal reflux. Patient heterogeneity combined with inadequate study methodology has led to enormous confusion in interpreting the relationship between Helicobacter pylori and non-ulcer dyspepsia. The possibility that H. pylori is associated with gastroesophageal reflux disease may explain, in part, the difficulty in establishing a link between non-ulcer dyspepsia and H. pylori infection. It is unclear whether the prevalence of H. pylori is increased in non-ulcer dyspepsia over and above the background population. H. pylori does not appear to be linked to heartburn or other specific upper gastrointestinal tract symptoms. The results of eradication trials in H. pylori-infected patients with non-ulcer dyspepsia have been equivocal and generally flawed. There is no doubt that H. pylori is not a sufficient cause of non-ulcer dyspepsia, because it is well documented in the literature that dyspepsia can occur in the absence of infection and infection can occur in the absence of symptoms. At this stage, there is insufficient evidence to support the hypothesis that H. pylori is etiologically linked to non-ulcer dyspepsia, but data from well designed large randomized controlled trials of eradication therapy are awaited with great interest.

INTRODUCTION

Definitions of dyspepsia have often included upper abdominal as well as reflux symptoms, which has led to considerable confusion in the literature [1, 2]. In order to try and clarify the situation, consensus-based definitions have been developed. The most widely accepted definition of dyspepsia, commonly referred to as the “Rome” definition, defines the condition as chronic or recurrent pain or discomfort centered in the upper abdomen [1]; it was concluded that those with heartburn alone or those in whom heartburn is the predominant complaint are most likely to have gastroesophageal reflux disease and should not be labelled as having dyspepsia, although this is often ignored [1].

A vexing question is the relationship between Helicobacter pylori gastritis and dyspepsia. Only a minority with dyspepsia have an obvious structural explanation such as chronic peptic ulcer disease [1-3]; the remainder are generally labelled as having non-ulcer (or functional) dyspepsia. While there is no dispute that H. pylori is causally linked to chronic peptic ulcer disease, the association with non-ulcer dyspepsia is highly controversial [3-6]. Of course, non-ulcer dyspepsia is a very poor term: it implies the presence of a disorder based on the absence of a disease, namely peptic ulcer. However, non-ulcer dyspepsia remains one of the most widely used terms in practice. Here, the link between non-ulcer dyspepsia and reflux and their
Upper abdominal pain

Heartburn

26% 56% 18%
807 1739 559

Figure 1. Distribution of upper abdominal pain (dyspepsia) and heartburn in a population-based study from the United Kingdom. From Reference [7] with permission.

association with *H. pylori* infection will be critically reviewed.

**HOW MUCH OF DYSPEPSIA IS EXPLAINED BY GASTROESOPHAGEAL REFLUX DISEASE?**

Whatever definition of dyspepsia is used, there is a considerable overlap of upper gastrointestinal tract symptoms in the general population. The majority of patients with upper abdominal symptoms who are labelled as having non-ulcer dyspepsia also have some heartburn [1]. Thus, Jones and Lydeard in a population-based survey from the United Kingdom reported that 56 percent of subjects with upper gastrointestinal symptoms had both heartburn and upper abdominal pain (Figure 1) [7], and these results have been confirmed in the United States and elsewhere [8-10]. There are surprisingly few data on the discriminant value of heartburn, but it has been reported that heartburn is an insensitive symptom for the detection of true gastroesophageal reflux disease. Klauser et al. found that heartburn had a sensitivity of only 38 percent for gastroesophageal reflux disease based on abnormal 24-hour esophageal pH testing, indicating that many people with this symptom will not have the disease [11]. Unfortunately, this was a flawed study because only very selected patients were included (namely those referred for 24-hour pH monitoring); symptom events were not evaluated in relation to pH change in the esophagus, and measurement of symptoms may not have been optimal.

The value of heartburn in identifying reflux disease must critically depend on how it is defined and measured. In a recent study based on a questionnaire, patients with a burning sensation in the epigastrium or lower retrosternal region that radiated up towards the neck described their main symptom as epigastric pain rather than as heartburn in 56 percent of cases [12]. Yet a burning sensation in the epigastrium or retrosternum that travels up towards the neck has an excellent positive predictive value for an abnormal 24-hour esophageal pH test or the presence of erosive esophagitis, and also is highly predictive of the response to proton pump inhibitor therapy over placebo [13]. These preliminary data support the concept that
symptom-based definitions of dyspepsia and heartburn can be more rigorous, and appropriate history taking may help to differentiate reflux from dyspepsia [14], but the current non-ulcer dyspepsia literature is contaminated by reflux patients [15, 16].

**IS H. PYLORI LINKED TO GASTROESOPHAGEAL REFLUX?**

The relationship between *H. pylori* and gastroesophageal reflux is currently unclear and has been reviewed recently elsewhere [17-19]. However, there appears to be increasing evidence for the following. Firstly, *H. pylori* infection is probably negatively associated with the presence of reflux esophagitis, at least in some populations. Thus, Werdmuller and Loffeld identified the prevalence of *H. pylori* to be significantly lower in patients with reflux esophagitis (34 percent) compared with patients who had a normal upper endoscopy (51 percent) [20]. Other studies have supported these observations [21-23] although some investigators have failed to detect a significant difference in the prevalence of *H. pylori* infection between those with and without reflux esophagitis [24]. The major limitation of the current literature is that a number of patients with endoscopy negative (non-erosive) reflux disease have presumably been included in the control groups, which may have confounded the detection of a negative relationship in some studies. These observations are important, however, because if *H. pylori* is really less common in patients with true gastroesophageal reflux disease, then this may account for some of the confusion in the dyspepsia literature as described below.

There is also some evidence that cure of *H. pylori* infection in duodenal ulcer disease may result in an increased incidence of reflux esophagitis. Thus, a recent study found that reflux esophagitis developed in approximately 26 percent of duodenal ulcer patients cured of the infection compared with 13 percent in those with persistent infection [25]. However, inclusion of adequate control groups has been lacking and both erosive and non-erosive changes have been lumped together, which may have confounded the observations [17, 25, 26].

Thus, *H. pylori* infection may protect against reflux esophagitis in a subset, perhaps because over the long term a proportion of infected patients have hypochlorhydria, which may or may not be related to atrophic gastritis [27-29] or because raised gastrin levels increase lower esophageal sphincter pressure [17]. Alternatively, the presence of the infection in the region of the gastric cardia may alter reflex responses that reduce the number of transient lower esophageal sphincter relaxations [17, 18]. On the other hand, patients with raised acid secretion from an antral-predominant infection may potentially be predisposed to reflux esophagitis [18, 19].

**IS THE PREVALENCE OF H. PYLORI INCREASED IN NON-ULCER DYSEPSIA?**

*H. pylori* infection is present in 40 to 90 percent of patients with non-ulcer dyspepsia based on a wide range of published studies [3-6]. While it has been reported that the prevalence of infection is higher than in control groups, appropriate controls have often not been studied adjusting for factors such as age, socio-economic status, ethnic background and history of peptic ulcer disease, which all affect the prevalence of *H. pylori* infection. Thus, in a Dutch study that evaluated otherwise healthy volunteers, there was an association between *H. pylori* and dyspepsia, but this disappeared when those with a past history of ulcer disease were excluded [30]. A recent meta-analysis has suggested that there is indeed a two-fold increased risk of dyspepsia overall in infected cases, but this study could not take into account the quality of the data included [3]. Indeed, how many patients with reflux in fact were mislabelled as having dyspepsia
remains an unknown quantity that may have variably affected the associations reported.

**IS H. PYLORI A CAUSE OF SPECIFIC DYSPEPTIC SYMPTOMS?**

A number of studies have investigated whether individual symptoms may be linked to *H. pylori* infection. No relationship between heartburn and *H. pylori* has been detected in most of the published studies [3-6]. However, Rosenstock et al. reported in a random sample of 3589 adult Danish subjects that heartburn was associated with *H. pylori* seropositivity [31]. Some studies have detected a link between other symptoms such as postprandial bloating [32], or epigastric pain or burning and *H. pylori* infection [33], but there is a total lack of consistency in the literature suggesting that many if not all of these associations are spurious [5].

Other studies have divided subjects with dyspepsia into symptom subgroups in order to try and detect whether there is a link between *H. pylori* and symptoms [34-36]. While these subgroups have been variably defined, the studies have universally failed to detect an association between reflux-like dyspepsia and *H. pylori* [34-36]. Similarly, no association between ulcer-like or dysmotility-like dyspepsia and *H. pylori* has been identified (Figure 2) [34, 36].

**DOES CURE OF H. PYLORI CURE NON-ULCER DYSPESIA?**

This remains one of the key questions, which as yet does not have a clear answer. A number of studies have investigated the effects of bismuth in non-ulcer dyspepsia, but the results have been conflicting, symptom reduction was variable and only suppression of infection was achieved in most cases [37]. A number of more recent studies have tested the efficacy of cure of *H. pylori* infection [38]. Interpretation of the eradication trials is difficult as the results have been conflicting [39-45]. Unfortunately, relatively few studies have been randomized, double-blind placebo-controlled trials that have employed adequate follow-up (although how long follow-up needs to be in order to have complete cure of gastritis is as yet...
Thus, El-Omar et al. have eradicated therapy, dominant H. pylori hypochlorhydric acid secretion become patients with non-ulcer dyspepsia more than six months follow up (1995-1997).

### Table 1. Randomized controlled trials of clinical efficacy of H. pylori eradication in patients with non-ulcer dyspepsia with more than six months follow up (1995-1997).

| Author          | Treatment       | No. | Double-blind | Placebo group included | Time to follow-up (months) | Results |
|-----------------|-----------------|-----|--------------|------------------------|---------------------------|---------|
| van Zanten et al. 1995, [39] | BSS + AMO + MTZ       | 53  | Yes          | Yes                    | 6                         | NS*     |
| Lazzaroni et al. 1996 [40] | CBS + MTZ vs. CBS + placebo | 41  | Yes          | Yes                    | 6 p <.05**                |         |
| Schutze et al. 1996 [41] | CLR + RAN            | 54  | No           | No                     | 12 NS**                   |         |
| Cucchiara et al. 1996 [42] | CBS + TIN + AMO 1 week vs. 4 weeks | 64  | No           | No                     | 6 NS**                   |         |
| Greenberg et al. 1996 [43] | CLR + OME            | 33  | Yes          | Yes                    | 1,3,6,12 NS*              |         |
| Sheu et al. 1996 [4] | CBS + AMO + MTZ vs. H2 blocker       | 41  | No           | No                     | 6 and 12 p <.01***        |         |
| Gilivary et al. 1997 [45] | CBS + MTZ + TET vs. CBS + placebo   | 100 | Uncertain    | Yes                    | 2, 6, 12 p <.01***        |         |

BSS, bismuth subsalicylate; MTA, metronidazole; CLR, clarithromycin; RAN, ranitidine; AMO, amoxicillin; CBS, colloidal bismuth subcitrate; TIN, tinidazole; OME, omeprazole; NS, not significant;*, comparison between patients with active treatment and placebo; **, comparison between patients with H. pylori eradicated and those with persistent infection or with persistent and current infections; ***, comparison between patients with H. pylori eradicated and those receiving other active therapy.

Not well enough defined (Table 1). It is also conceivable that a small minority of patients with non-ulcer dyspepsia may become worse because reflux symptoms are induced by H. pylori eradication. Thus, El-Omar et al. have reported among hypochlorhydric subjects with body-predominant H. pylori gastritis that gastric acid secretion increased in 12 of 15 after eradication therapy, and six of 15 developed heartburn [27]. A number of large well designed randomized controlled trials will be available in the near future, which hopefully will shed new light in this confusing area.

### REFERENCES

1. Talley, N.J., Colin-Jones, D., Koch, K.L., Koch, M., Nyren, O., and Stanghellini, V. Functional dyspepsia: a classification with guidelines for diagnosis and management. Gastroenterol. Int. 4:145-116, 1991.
2. Knill-Jones, R.P. Geographical differences in the prevalence of dyspepsia. Scand. J. Gastroenterol. 26(suppl 182):17-24, 1991.
3. Armstrong, D. Helicobacter pylori infection and dyspepsia. Scand. J. Gastroenterol. 31(suppl 215):38-47, 1996.
4. Lambert, J.R. The role of Helicobacter pylori in non-ulcer dyspepsia — a debate: for. Gastroenterol. Clin. N. Am. 22:141-151, 1993.
5. Talley, N.J. The role of Helicobacter pylori in non-ulcer dyspepsia — a debate: against. Gastroenterol. Clin. N. Am. 22:153-167, 1993.
6. Van zanten, S.J.O.V. The role of Helicobacter pylori infection in non-ulcer dyspepsia. Aliment. Pharmacol. Ther. 11(suppl 1):A63-69, 1997.
7. Jones, R. and Lydeard, S. Prevalence of symptoms of dyspepsia in the community. Br. Med. J. 298:30-32, 1989.
8. Talley, N.J., Zinsmeister, A.R., Schleck, C.D., and Melton, L.J., III. Dyspepsia and
dyspepsia subgroups: a population-based study. Gastroenterology 102:1259-1268, 1992.

9. Locke, G.R., Talley, N.J., Fett, S.L., Zinsmeister, A.R., and Melton, L.J. Prevalence and clinical spectrum of gastroesophageal reflux - a population-based study in Olmsted County, Minnesota. Gastroenterology 112:1448-1456, 1997.

10. Agreus, L., Svardsudd, K., Nyren, O., and Tibblin, G. Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time. Gastroenterology 109:671-680, 1995.

11. Klauser, A.G., Schindlbeck, N.E., and Muller Lissner, S.A. Symptoms in gastroesophageal reflux disease. Lancet 335:295-298, 1990.

12. Carlsson, R., Dent, J., Glise, H., Riley, S., Torgfard, K., and Junghard, O. Evaluation of a questionnaire for the diagnosis of symptomatic gastroesophageal reflux disease (GERD). Gastroenterology 110:A76, 1996.

13. Carlsson, R., Bolling, E., Jerndal, P., Junghard, O., Lauritsen, K., and Glise, H. Factors predicting response to omeprazole treatment in patients with functional dyspepsia. Gastroenterology 110:A76, 1996.

14. Headin, R.C., Wager, E., and Tooley, P.J.H. Reliability of symptom assessment in dyspepsia. Eur. J. Gastroenterol. Hepatol. 9:779-781, 1997.

15. Small, P.K., Loudon, M.A., Waldron, B., Smith, D., and Campbell, F.C. Importance of reflux symptoms in functional dyspepsia. Gut 36:189-192, 1995.

16. Pfeiffer, A., Aronbayev, J., Schmidt, T., Wendl, B., Pehl, C., and Kaessler, H. Gastric emptying, esophageal 24-hour pH and gastric potential difference measurements in non-ulcer dyspepsia. Gastroenterol. Clin. Biol. 16:395-400, 1992.

17. Labenz, J. and Malfertheiner, P. Helicobacter pylori in gastro-oesophageal reflux disease: causal agent, independent or protective factor? Gut 41:277-280, 1997.

18. Vicari, J., Falk, G.W., and Richter, J.E. Helicobacter pylori and acid peptic disorders of the esophagus — is it conceivable? Am. J. Gastroenterol. 92:1097-1102, 1997.

19. Xia, H.H.X. and Talley, N.J. Helicobacter pylori infection, reflux esophagitis and atrophic gastritis: an unexplored triangle. Am. J. Gastroenterol. (In press)

20. Werdmuller, B.F.M. and Loffeld, R.J.L.F. Helicobacter pylori infection has no role in the pathogenesis of reflux esophagitis. Dig. Dis. Sci. 42:103-105, 1997.

21. Befrirts, R., Granstrom, M., Rylander, M., Rubio, C. Helicobacter pylori in 205 consecutive endoscopy patients. Scand. J. Infect. Dis. 25:185-191, 1993.

22. Cheng, E.H., Bermanski, P., Silversmith, Valenstein, P., and Kawanishi, H. Prevalence of Campylobacter pylori in esophagitis, gastritis, and duodenal disease. Arch. Intern. Med. 149:1373-1375, 1989.

23. Liston, R., Pitt, M.A., and Banerjee, A.K. Reflux esophagitis and Helicobacter pylori infection in elderly patients. Postgrad. Med. J. 72:221-223, 1996.

24. Newton, M., Bryan, R., Burnham, W.R., and Kamm, M.A. Evaluation of Helicobacter pylori in reflux esophagitis and Barrett’s esophagitis. Gut 40:9-13, 1997.

25. Labenz, J., Blum, A.L., Bayerdorffer, E., Meining, A., Stolte, M., and Borsch, G. Curing Helicobacter pylori infection in patients with duodenal ulcer may provoke reflux esophagitis. Gastroenterology 112:1442-1447, 1997.

26. Sacca, N., De Medici, A., Rodino, S., and Giglio, A. Reflux esophagitis: a complication of Helicobacter pylori (HP) eradication therapy. Gut 39(suppl 3):A35, 1996.

27. El-Omar, E.M., Oien, K., El-Nuyumi, A., Gillen, D., Wirtz, A., Dahill, S., Williams, C., Ardill, J.E.S., and McColl, K.E.L. Helicobacter pylori infection and chronic gastric acid hyposecretion. Gastroenterology 113:15-24, 1997.

28. Kuipers, E.J., Lundell, L., Klinkenberg-Knol, E.C., Havu, N., Festen, H.P.M., Liedman, B., Lamers, C.B.H.W., Jansen, J.B.M.J., Dalenback, J., Snel, P., Nelis, G.F., and Meuwissen, S.G.M. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. N. Engl. J. Med. 334:1018-1022, 1996.

29. Kuipers, E.J., Uiterlande, A.M., Pena, A.S., Rovsendaal, R., Pals, G., Nelis, G.F., Festen, H.P.M., and Meuwissen, S.G.M. Long-term sequelae of Helicobacter pylori-associated gastritis. Lancet 345:1525-1528, 1995.

30. Schlemper, R.J., van den Werf, S.D.J., Vandenbroucke, J.P., Biemond, I., and Lamers, C.B.H.W. Non-ulcer dyspepsia in a Dutch working population and Helicobacter pylori. Arch. Intern. Med. 155:82-87, 1995.

31. Rosenstock, S., Kay, L., Rosenstock, C., Andersen, L.P., Bonnevie, O., and Jorgensen, T. Relation between Helicobacter pylori infection and gastrointestinal symptoms and syndromes. Gut 41:169-176, 1997.

32. Rokkas, T., Pursey, C., Uzoechina, E., Dorrington, L., Simmons, N.A., Filipe,
39. Tucci, A., Corinaldesi, R., Stanghellini, V., Tosetti, C., di Febo, G., Paparo, F., Varoli, O., Paganelli, G., Morselli Labate, A., Masci, C., Zoccoli, G., Monetti, N., and Barbara, L. *Helicobacter pylori* infection and gastric function in patients with chronic idiopathic dyspepsia. Gastroenterology 103:768-774, 1992.

40. Holtmann, G., Goebell, H., Holtmann, M., and Talley, N.J. Dyspepsia in healthy blood donors: pattern of symptoms and association with *Helicobacter pylori*. Dig. Dis. Sci. 39:1090-1098, 1994.

41. Agreus, L., Engstrand, L., Svardssudd, K., Nyren, O., and Tibblin, G. *Helicobacter pylori* seropositivity among Swedish adults with and without abdominal symptoms: a population-based epidemiologic study. Scand. J. Gastroenterol. 30:752-757, 1995.

42. Nandurkar, S., Talley, N.J., Xia, H.H.-X., Patiag, D., Hazel, S., Mitchell, H., and Jones, M. Dyspepsia in the community is linked to smoking and aspirin use but not to *Helicobacter pylori*. Gastroenterology 112:A232, 1997.

43. Talley, N.J. A critique of therapeutic trials in *Helicobacter pylori*-positive functional dyspepsia. Gastroenterology 106:1174-1183, 1994.

44. Laheij, R.J.F., Jansen, J.B.M.J., Van Da Linsnik, E.H., Severens, J.L. and Verbeek, A.L.M. Review article: symptom improvement through eradication of *Helicobacter pylori* in patients with non-ulcer dyspepsia. Aliment. Pharmacol. Ther. 10:843-850, 1996.

45. Vedhuyzen van Zanten, S.J.O., Malatjilian, D., Tanton, R., Leddin, D., Hunt, R.H., and Blanchard, W. The effect of eradication of *H. pylori* on symptoms of non-ulcer dyspepsia: a randomized double-blind placebo controlled trial. Gastroenterology 108:A250, 1995.

46. Lazzaroni, M., Bargigia, S., Sangaletti, O., Maconi, G., Boldorini, M., and Bianchi Aporro, G. Eradication of *Helicobacter pylori* and long-term outcome of functional dyspepsia. A clinical endoscopic study. Dig. Dis. Sci. 41:1589-1594, 1996.

47. Schutze, K., Hentschel, E., and Hirschel, A.M. Clarithromycin or amoxycillin plus high-dose ranitidine in the treatment of *Helicobacter pylori*-positive functional dyspepsia. Eur. J. Gastroenterol. Hepatol. 8:41-46, 1996.